Nicaragua
Tuberculosis profile
Population  2012 6 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.19 (0.15–0.23) 3.1 (2.4–3.8)
Mortality (HIV+TB only) <0.01 (<0.01–0.013) 0.09 (0.07–0.22)
Prevalence  (includes HIV+TB) 3.3 (1.1–6.7) 55 (19–112)
Incidence  (includes HIV+TB) 2.3 (2–2.7) 38 (33–44)
Incidence (HIV+TB only) 0.047 (0.028–0.07) 0.78 (0.47–1.2)
Case detection, all forms (%) 120 (110–140)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 484 (56) Relapse 150 (51)
Smear-negative 817 (31) Treatment after failure 17 (6)
Smear-unknown / not done 0 (0) Treatment after default 127 (43)
Extrapulmonary 339 (13) Other 0 (0)
Other 0 (0)      
Total new 2 640   Total retreatment 294  
           
Other (history unknown) 0        
Total new and relapse 2 790   Total cases notified 2 934  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio   1.1 1.1
Age < 15 0 0  
Laboratories 2012
Smear (per 100 000 population) 3.2
Culture (per 5 million population) 1.7
Drug susceptibility testing (per 5 million population) 0.8
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment 69  
TB/HIV 2012 Number (%)
TB patients with known HIV status 2 117 (72)
HIV-positive TB patients 105 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 82 (78)
HIV-positive TB patients on antiretroviral therapy (ART) 78 (74)
HIV-positive people screened for TB 103  
HIV-positive people provided with IPT 230  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.63 (0.08–2.2) 11 (6.2–17)
MDR-TB cases among notified pulmonary
TB cases
14 (2–52) 31 (18–49)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB     103
Laboratory-confirmed MDR-TB cases     21
Patients started on MDR-TB treatment     9
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data